Tag: relapsed and refractory lymphoma

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

byJessie Willisand1 others

December 2, 2021

1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...

$#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas$

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

byKathleen Lau

September 16, 2021

$#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin’s Lymphoma$

#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin’s Lymphoma

byKathleen Lau

August 20, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result